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unrelenting itching. No longer will people be
threatened by gross deformity from ﬁlaria-
sis. Irrespective of personal views on the
merits or achievability of malaria eradica-
tion, it is the conﬁdence in the availability of
fast acting and highly effective ﬁrst, second
or third generation ACTs that has contrib-
uted to the debate to ensure we are in a
position where we do have the tools to
attempt the audacious challenge of
regional elimination. Eradication is, at pres-
ent, an aspirational goal without powerful
new tools and needs to be placed in the
context of the deﬁnition of eradication –
‘global zero incidence of a speciﬁc
organism’. Nevertheless, in the absence
of the work of Youyou Tu and her team
at Mission 523, it is probable that malaria
would currently be a disease on the rise and
one where treatment options were
severely, life-threateningly limited. Millions
of lives have been saved by the availability
of ACTs and as cases fall [10] and we move
away from the hideous statistic of more
than 1 million lives, mainly children, lost
per year to this treatable infection, we enter
a future where a world without the disease
can be contemplated with signiﬁcant eco-
nomic beneﬁts for endemic countries [11].
Whatever the future, we are much better
placed to treat malaria now than where we
were before the availability of ACTs. In
reﬂecting on this Nobel Prize, it is clear that
many parallels can be drawn between the
discovery, development, deployment and
eventual impact of ivermectin and artemi-
sinin. The malaria and helminth scientiﬁc
and public health communities did not
interface and, instead, developed indepen-
dently. However, to achieve public health
impact, common approaches were
needed – public—private partnerships,
global advocacy, NGDO involvement, sub-
sidised pricing mechanisms or drug dona-
tions. Such processes deﬁne the complex
path from scientiﬁc discovery, through to
global health policy change, implementa-
tion, monitoring and evaluation to ensure
the poorest communities beneﬁt fromaccess to critical medicines. Whilst much
remains to be done and many challenges
remain, the Nobel Committee has made an
enlightened decision – to recognize the
science that has led to making the lives
of millions of the poorest signiﬁcantly better
than it was 50 years ago. In the next dec-
ades, with malaria and NTDs now embed-
ded within the United Nations Sustainable
Development Goals, the drugs developed
by Campbell, O¯mura and Youyou Tu will be
critical to achieve the targets for these dis-
eases established by the international
development community – some drugs,
some legacy!
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The 2015 Nobel Prize for Medicine
or Physiology was awarded to Wil-
liam C. Campbell and Satoshi
O¯mura for their discovery of aver-
mectins, and to Tu You You for her
contribution to the discovery of
artemisinin. The discovery and
development of qinghaosu (artemi-
sinin) as an antimalarial drug is a
remarkable and convoluted tale.
In the mid-1960s, in the immediate after-
math of the Cultural Revolution, China
responded to requests from North Viet-
nam for help in their impending conﬂict.
Malaria had played a major role in the ﬁrst
and second World Wars, and it had nearly
killed Ho Chi Minh in 1945. Ho knew
malaria could be a decisive factor in the
forthcoming struggle. Malaria was still a
signiﬁcant problem in China too and so
scientists across the land were ordered to
ﬁnd effective remedies, both in modern
pharmaceutical chemistry and also in
the extensive traditional medicine pharma-
copoeia. On the 23 of May 1967, Project
523 was formed. This remarkable truly
multicentre collaboration discovered the
antimalarial properties of organic extracts
of the leaves of Artemisia annua, a tradi-
tional febrifuge, identiﬁed the antimalarial
moieties, determined their chemical
structures, and characterized their phys-
ico-chemical properties and their antima-
larial activities, ﬁrst in animal models, and
then in human malaria [1]. Initially there
was some confusion over the plant; was
it qinghao or huanghuahao that had the
magical antimalarial properties?nds in Parasitology, December 2015, Vol. 31, No. 12 607
of the physicochemical properties, antima-
larial activity, and clinical evaluation of arte-
misinin in the Chinese Medical Journal [2]
(Figure 1). Slowly, the news spread.
Thereafter things went neither smoothly or
quickly. The Chinese interaction with TDR,
the World Health Organization (WHO) Spe-
cial Programme for Research and Training
in Tropical Diseases, which had a strong
US Army representation at the time, was
uneasy and ultimately fruitless. With dubi-
ous scientiﬁc justiﬁcation, TDR decided to
develop the ethyl ether (arteether) of dihy-
droartemisinin as a new drug, rather than
the methyl ether (artemether) produced by
a Chinese pharmaceutical company (the
Chinese had actually synthesized arteether
but rejected it in favour of artemether).
Questions were raised over the quality of
the Chinese drugs, and the stability of the
water soluble artesunate. WHO TDR and
the US Army decided initially to focus only
on the intramuscular oil based injections
and not to develop oral or intravenous
drugs, which today form the mainstay of
antimalarial treatment (http://apps.who.
int/iris/bitstream/10665/61147/1/TDR_
CHEMAL_ART_86.3.pdf). Meanwhile,
antimalarial drug resistance continued
to worsen in Southeast Asia. Effective
alternatives treatments were needed
desperately. Asian investigators, tired of
waiting for the ‘quality’ products prom-
ised by WHO, began studies with Chinese
oral, parenteral and rectal formulations in
Myanmar, Vietnam (which by the late
1980s was producing its own artemisi-
nin), Thailand [5–7] and soon after in Africa
[8]. These rapidly conﬁrmed the original
Chinese claims.
The ﬁrst large randomized controlled trials
in severe malaria, which started in 1991,
glish Describing the Discovery and Development of Qinghaosu.Misidentiﬁcation delayed proceedings but
once the correct plant extract was used, it
was clear that the active moiety (now
called qinghaosu, or later–artemisinin)
was an extremely active antimalarial.
Indeed it produced the most rapid para-
site clearance of any known antimalarial
drugs. Skillful chemistry then produced
the reduction derivative dihydroqinghaosu
(dihydroartemisinin) which was even more
potent, and this served as the basis for
stable lipophilic and hydrophilic derivatives
(artemether and artesunate, respectively).
Led by Professor Li Guo Qiao, a professor
of traditional Chinese medicine from
Guangzhou, clinical trials were conducted
which conﬁrmed the extraordinary antima-
larial activity of these compounds both in
uncomplicated and cerebral malaria [2–4].
In 1979 the Qinghaosu Antimalaria Coordi-
nating Research Group published a
remarkable succinct description (in English)
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were with Chinese artemether [9]. These
showed superiority in terms of mortality
reduction in adults from Southeast Asia,
but not in African children and left sufﬁcient
equipoise that quinine (another venerable
plant derived compound) remained as the
treatment of choice [10]. The oral drugs
(artemisinin, artesunate, or artemether)
were rapidly effective and well tolerated
but as monotherapies they required treat-
ment courses of 5 and 7 days in vivax and
falciparum malaria, respectively. Combi-
nations with more slowly eliminated anti-
malarial drugs proved highly effective and,
eventually, 3-day treatments became
established [4,6,7]. The excellent tolerabil-
ity and efﬁcacy of the artemisinin-based
combination therapies (ACTs) in
Southeast Asia eventually led to conﬁrma-
tory trials in South America and across
Africa, which began in the late 1990s
[7]. Although the artemisinin derivatives
were very well tolerated as well as being
rapidly effective there were two prevailing
safety concerns at the time; ﬁrst, repeated
high injected doses of the oil based
arteether (and artemether) caused an
unusual pattern of selective neurotoxicity
affecting certain brain stem nuclei in
rodents and beagle dogs; second, arte-
misinins were embryotoxic. Fortunately,
neurotoxicity was never conﬁrmed in
humans, but until recently artemisinins
were contraindicated in the ﬁrst trimester
of pregnancy in uncomplicated malaria
infections, although there is increasing evi-
dence for safety in early pregnancy.
During the 1990s it became increasingly
clear that the continued use of inexpensive,
yet ineffective, antimalarial drugs (chloro-
quine and then sulphadoxine-pyrimeth-
amine) by most malaria endemic
countries was killing millions of people
(most of whom were children in Africa).
Meanwhile, the evidence that ACTs were
highly effective and well tolerated had
grown steadily. The consistently good
results from Asia were replicated else-
where and toxicity concerns receded [7–
10]. The debate between malaria research-
ers, non-governmental organizations(NGOs), and growing numbers of malaria
control programme representatives who
argued strongly for deployment of these
drugs, and the donors and international
organisations who were reluctant to sup-
port them, became increasingly heated
[11]. Finally in 2006, 27 years after the ﬁrst
seminal publication in English (Figure 1),
the WHO decided clearly and unequivo-
cally to recommend ACTs as ﬁrst line treat-
ment of uncomplicated falciparum malaria
in all endemic countries [12]. At the same
time, the WHO raised the bar substantially
in the minimum efﬁcacy required of an
antimalarial treatment – malaria control
programmes everywhere were now
requested to aim for 28-day ‘cure’ rates
of 95% and to change policy if cure rates
fell below 90% [12]. Previously it had been
considered acceptable for failure rates
assessed at 14 days to be as high as
25% (which corresponded to true failure
rates over 50%).
The rapid parasite clearance caused by
the artemisinins and the associated
speedy clinical recovery had long sug-
gested that these compounds conferred
a survival beneﬁt in severe malaria. Unfor-
tunately, because the oil-based intramus-
cular formulations (artemether, arteether)
were then the compounds favoured by the
WHO, these were the ﬁrst to be evaluated
in large randomized trials in severe
malaria. The results were not sufﬁciently
powerful to change practice [10], probably
because these oil based intramuscular
drugs are slowly and unreliably absorbed
from the injection site. In contrast, the
water-soluble artesunate can be given
intravenously and is rapidly and reliably
absorbed following intramuscular injec-
tion. Belatedly in 2003 multicentre ran-
domized trials with parenteral artesunate
began in Asia. These showed a substantial
(35%) reduction in mortality compared
with quinine [13]. This result was sufﬁcient
for policy change outside Africa, and it
paved the way for the largest randomized
controlled trial in African children hospital-
ised with severe malaria (AQUAMAT) [14].
The AQUAMAT trial showed a 22.5%
Trelower mortality in children who received
artesunate compared with those who
received quinine. This coincided with
removal of lingering concerns over drug
quality and led to a uniform recommenda-
tion for parenteral artesunate as the
treatment of choice for severe malaria
everywhere.
In recent years substantial increases in
international funding for malaria control
have resulted in widespread deployment
of ACTs in nearly all malaria endemic
areas, and contributed to a substantial
decline in global malaria morbidity and
mortality (World Malaria Report 2014:
http://www.who.int/malaria/publications/
world_malaria_report_2014/en). Malaria
elimination is again on the political agenda.
Although there are formidable obstacles
to this ambitious goal, it cannot be
achieved without effective antimalarial
medicines. In January 2006, the WHO
recognized the risks of artemisinin resis-
tance arising from decades of poorly reg-
ulated use and widespread availability of
falsiﬁed and sub-standard medicines,
and pushed strongly for a ban on mono-
therapies, but unfortunately, this was too
late to prevent the emergence of resis-
tance to artemisinin. Today artemisinin
resistant Plasmodium falciparum can
be found across Southeast Asia from
the coast of Vietnam to the Myanmar–
India border [15]. Predictably, uncon-
tained resistance to artemisinin has led
to worsening resistance to the ACT
partner drugs. The prospect of drug
resistant malaria parasites spreading
from Southeast Asia through India to
Africa and killing millions of children for
a third time has rightly excited alarm, and
provoked numerous meetings and
resolutions, but it has not resulted in a
radical containment strategy. For most of
the malaria affected world, there is no
evidence yet that the products of this
remarkable Chinese traditional medicine
are failing – but continued vigilance is
needed. Loss of the artemisinins would
deal a devastating blow to our renewed
ambitions to eliminate malaria.
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Bradyzoite forms of Toxoplasma
gondii persist in tissue cysts for
the lifetime of an infected host
and can reactivate to cause clinical
disease. It was thought that in vivo
bradyzoites within tissue cysts are
biologically inactive dormant forms
that rarely replicate. Apparently,
consensus was wrong.
The opportunistic pathogen Toxoplasma
gondii is an Apicomplexan parasite that
has the unique ability to persist within its
host as latent bradyzoite forms that lie
within tissue cysts. The rapidly growing
tachyzoite form that is responsible for clin-
ical disease is controlled by the immune
system and differentiates into bradyzoites.
Bradyzoites have unique antigens and
metabolism that are presumed to protect
bradyzoite contents of cysts harvested
at different times from mouse brains.
Ninety-nine cyst preparations, 630 cysts,
and two years later, they found that more
goes on within tissue cysts than had been
appreciated previously.
Bradyzoite biology has been difﬁcult to
study. In the laboratory, bradyzoite differ-
entiation can be induced by various envi-
ronmental stresses, but it is difﬁcult to
obtain pure populations of bradyzoites
that are not contaminated with tachyzoite
forms. Strains of T. gondii differ in their
propensity to differentiate, and strains
cultivated in the laboratory gradually lose
their ability to differentiate. Epigenetic
gene regulation also plays an important
role in the tachyzoite-bradyzoite transi-
tion, but the exact molecular triggers for
differentiation are not understood, as it
has not been possible to follow the pro-
gression of bradyzoite differentiation over
time. There has been controversy in the
ﬁeld whether laboratory induced brady-
zoites are ‘real’ bradyzoites, with brady-
zoites harvested from tissue cysts serving
as the gold standard reference. It has
been assumed that in vivo bradyzoites
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facilitate long-term viability in tissue [1]
(Figure 1). Bradyzoites are important
because they can reactivate to cause
lethal disease in an immunocompromised
host. Although T. gondii can infect all
nucleated cells, cysts are common in
the brain, and clinical toxoplasmosis often
presents as encephalitis, acute inﬂamma-
tion of the brain. Bradyzoites are also
infectious when ingested. So the biology
of bradyzoites has been the subject of
intense interest to scientists investigating
pathogenesis of toxoplasmosis.
Recently, Watts et al. took a closer look at
the dynamics of T. gondii bradyzoites
within tissue cysts [2]. After painstakingly
optimizing the classic puriﬁcation protocol
developed by Cornelissen [3], Watts et al.
examined the size, density, and2standardized quantitation and character-
ization of cysts by Watts et al. [2] reveals
unexpected heterogeneity amongst bra-
dyzoites and tissue cysts.
Taking advantage of advances in three-
dimensional digital confocal imaging, the
authors developed the BradyCount soft-
ware that enabled them to accurately and
efﬁciently determine bradyzoite number
within cysts. In general, as expected, as
cyst size increased, the numbers of bra-
dyzoites within cysts increased. They also
carefully measured cyst size and used
digital imaging approaches to quantify
parasite division within cysts.
There was a surprisingly amount of vari-
ability in cyst density and bradyzoite bur-
den within individual cysts, suggesting
